Background: Myocardial reperfusion following prolonged ischemia may paradoxically cause additional injury, including edema and microvascular damage. These structural alterations augment tissue echogenicity measurable by integrated backscatter (IB). We sought to characterize alterations of myocardial IB in an ischemic and then reperfused region of the rat heart. Methods: Myocardial IB in 12 adult male Sprague-Dawley rats was studied at baseline, 60 minutes after left anterior descending coronary artery occlusion, and chronologically after coronary reopening. Short-axis scans of the mid left ventricle were acquired at a frequency of 8 MHz. Mean±SD values of IB were measured in the region of interest at baseline, ischemia, and reperfusion, and assessed by a paired t-test. Results: See figure and table. IB did not significantly change between baseline and ischemia. However, within 1 minute of reperfusion, IB significantly increased, as compared to both baseline and ischemia, and continued to increase until 10 minutes after reperfusion, when a plateau was reached. Conclusions: Myocardial reperfusion following acute prolonged ischemia in a rat heart significantly augments tissue echogenicity. A continuing increase of IB within minutes of the reperfusion onset and the subsequent plateau of elevated IB values suggest progression and completion, respectively, of reperfusion injury, detectable by a high-frequency transducer.
Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague–Dawley rats
Pharmacokinetics of drugs may differ between small and large mammals (including humans); therefore, drug testing in animal models must be carefully designed. Sprague–Dawley rats were used in cardiac experiments, during which the lopinavir concentration in serum had to match human therapeutic levels (4–10 μg/mL). Lopinavir was administered as a co-formulated drug of lopinavir and ritonavir. It was found that after a single administration of a standard human peroral dose (lopinavir 13.3 mg/kg of body weight), the serum concentration of lopinavir was only one-tenth of the target level. It remained below the minimum target level even after 10-fold the standard dose was administered. After initial pilot tests, a dose escalation study was conducted with oral doses 10- and 15-fold the standard clinical dose of lopinavir (i.e. 133 and 200 mg/kg, respectively). A second administration 2 h later effectively increased and maintained higher concentrations during the experimental ischaemia and reperfusion periods. A dose-dependent increase in serum concentration of the drug was observed. Thus, the target therapeutic serum level of lopinavir in the rats was achieved by administrating 10- to 15-fold the standard human dose twice, separated by a 2 h interval.
Constrictive Pericarditis and Restrictive Cardiomyopathy in the Modern Era